1. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
- Author
-
Sid E. O'Bryant, Simone Lista, Robert A. Rissman, Melissa Edwards, Fan Zhang, James Hall, Henrik Zetterberg, Simon Lovestone, Veer Gupta, Neill Graff‐Radford, Ralph Martins, Andreas Jeromin, Stephen Waring, Esther Oh, Mitchel Kling, Laura D. Baker, Harald Hampel, ISTAART Blood Based Biomarker Professional Interest Area, University of North Texas Health Science Center [Fort Worth], Institute for Aging and Alzheimer’s Disease Research [Fort Worth] (IAADR), Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] (IM2A), Université Pierre et Marie Curie - Paris 6 (UPMC), AXA Research Fund, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), UC San Diego School of Medicine, University of North Texas (UNT), UCL Institute of neurology, UCL Institute of Neurology, Department of Psychiatry and Neurochemistry [Goteborg], Institute of Neuroscience and Physiology [Göteborg]-Sahlgrenska Academy at University of Gothenburg [Göteborg], Psychiatry Institute, King‘s College London, Center of Excellence for Alzheimer's Disease Research and Care, Mayo Clinic [Jacksonville], Quanterix Corp, Essentia Institute of Rural Health, Texas Alzheimer's Research and Care Consortium, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine Baltimore, Perelman School of Medicine, University of Pennsylvania [Philadelphia], Wake Forest School of Medicine [Winston-Salem], Wake Forest Baptist Medical Center, Institut de la Mémoire et de la Maladie d'Alzheimer [CHU Pitié-Salpétriêre] (IM2A), Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), School of Medicine [Univ California San Diego] (UC San Diego), University of California [San Diego] (UC San Diego), University of California (UC)-University of California (UC), University of Pennsylvania, and HAL-UPMC, Gestionnaire
- Subjects
Serum ,0301 basic medicine ,Aging ,Pathology ,Disease ,lcsh:Geriatrics ,Neurodegenerative ,lcsh:RC346-429 ,Plasma ,chemistry.chemical_compound ,0302 clinical medicine ,Pancreatic polypeptide ,Alzheimer's Disease including Alzheimer's Disease Related Dementias ,Meso Scale Discovery ,Multiplex ,Biomarker discovery ,Diagnostics ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Factor VII ,Interleukin ,Blood-Based Biomarkers ,Alzheimer's disease ,Psychiatry and Mental health ,Blood ,medicine.medical_specialty ,Preanalytic processing ,03 medical and health sciences ,Clinical Research ,Acquired Cognitive Impairment ,Genetics ,medicine ,Serum amyloid A ,Multiplex assay platform ,lcsh:Neurology. Diseases of the nervous system ,Rules Based Medicine ,business.industry ,Beta-2 microglobulin ,Neurosciences ,Proteins ,Standardization ,Brain Disorders ,4.1 Discovery and preclinical testing of markers and technologies ,lcsh:RC952-954.6 ,030104 developmental biology ,chemistry ,Immunology ,Dementia ,Neurology (clinical) ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,030217 neurology & neurosurgery - Abstract
International audience; Introduction : This study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms.Methods : Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots.Results : On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70).Discussion : The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.
- Published
- 2016